Title: Strategic Priorities – Diabetes Therapeutics Portfolio

Date: July 2023

Overview:
This internal strategic deck outlines the company’s 5-year roadmap for diabetes therapeutics. The focus remains on differentiated formulations targeting metabolic efficiency and cardiovascular safety.

Strategic Pillars:

Diversification: Expand beyond metformin generics into GLP-1 analogs (Semaglutide) and SGLT2 inhibitors.

Localization: Strengthen manufacturing base in India for cost leadership in emerging markets.

Innovation: Accelerate pipeline development for non-obese Type 2 diabetes phenotypes.

Patient-Centricity: Incorporate digital adherence tools with drug regimens.

Competitive Landscape:

Strong competition from Novo Nordisk and Eli Lilly in GLP-1 class.

Biosimilar opportunities opening post-2026 patent expirations.

Rapid uptake of oral anti-diabetic combinations in Southeast Asia.

Market Positioning:
We aim to position our brand as “Affordable innovation in metabolic care”, leveraging in-house formulation capabilities and adaptive regulatory pathways.